Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study
March 31st 2023Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
November 25th 2022Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.